The Manufacturers Life Insurance Company Has $316,000 Holdings in MiMedx Group, Inc. (NASDAQ:MDXG)

The Manufacturers Life Insurance Company grew its position in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 7.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,623 shares of the company’s stock after acquiring an additional 3,222 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in MiMedx Group were worth $316,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Millennium Management LLC increased its holdings in shares of MiMedx Group by 339.9% during the second quarter. Millennium Management LLC now owns 889,446 shares of the company’s stock valued at $6,164,000 after acquiring an additional 687,267 shares in the last quarter. Dark Forest Capital Management LP increased its holdings in shares of MiMedx Group by 13.4% during the second quarter. Dark Forest Capital Management LP now owns 153,020 shares of the company’s stock valued at $1,060,000 after acquiring an additional 18,054 shares in the last quarter. Marshall Wace LLP increased its holdings in shares of MiMedx Group by 1.1% during the second quarter. Marshall Wace LLP now owns 298,818 shares of the company’s stock valued at $2,071,000 after acquiring an additional 3,223 shares in the last quarter. Paradigm Capital Management Inc. NY increased its holdings in shares of MiMedx Group by 6.6% during the second quarter. Paradigm Capital Management Inc. NY now owns 4,167,200 shares of the company’s stock valued at $28,879,000 after acquiring an additional 258,700 shares in the last quarter. Finally, Hsbc Holdings PLC increased its holdings in shares of MiMedx Group by 7.3% during the second quarter. Hsbc Holdings PLC now owns 34,343 shares of the company’s stock valued at $233,000 after acquiring an additional 2,329 shares in the last quarter. Institutional investors own 79.15% of the company’s stock.

Analysts Set New Price Targets

MDXG has been the subject of several recent research reports. StockNews.com downgraded MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Craig Hallum decreased their price target on MiMedx Group from $14.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, August 1st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $11.00 target price on shares of MiMedx Group in a research note on Thursday, August 1st. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $12.00.

MiMedx Group Stock Down 0.3 %

Shares of NASDAQ MDXG opened at $5.83 on Friday. The company has a quick ratio of 3.22, a current ratio of 3.85 and a debt-to-equity ratio of 0.11. The company has a market cap of $860.53 million, a P/E ratio of 13.25 and a beta of 1.97. MiMedx Group, Inc. has a 52 week low of $5.47 and a 52 week high of $9.27. The business has a 50-day simple moving average of $6.16 and a two-hundred day simple moving average of $6.73.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.08 EPS for the quarter, meeting analysts’ consensus estimates of $0.08. The company had revenue of $87.21 million during the quarter, compared to analyst estimates of $88.44 million. MiMedx Group had a net margin of 23.63% and a return on equity of 34.24%. Research analysts anticipate that MiMedx Group, Inc. will post 0.26 earnings per share for the current fiscal year.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.